Trials / Sponsors / ImmuneMed, Inc.
ImmuneMed, Inc.
Industry · 7 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Unknown | A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumati Moderate to Severe Rheumatoid Arthritis | Phase 2 | 2024-03-01 |
| Unknown | A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) Chronic Hepatitis B | Phase 2 | 2022-01-11 |
| Terminated | Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia COVID-19 | Phase 2 | 2021-03-18 |
| Completed | Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia COVID-19 | Phase 2 | 2020-12-17 |
| Completed | Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia COVID-19 | Phase 2 | 2020-12-11 |
| Completed | Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administra Healthy Volunteers | Phase 1 | 2020-09-16 |
| Completed | Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers Healthy | Phase 1 | 2018-11-20 |